Cargando…

NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug

BACKGROUND: Most DNA-damaging chemotherapeutic agents activate the transcription factor nuclear factor κB (NF-κB). However, NF-κB activation can either protect from or contribute to the growth suppressive effects of the agent. We previously showed that the DNA-methylating drug temozolomide (TMZ) act...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caporali, Simona, Levati, Lauretta, Graziani, Grazia, Muzi, Alessia, Atzori, Maria Grazia, Bonmassar, Enzo, Palmieri, Giuseppe, Ascierto, Paolo A, D’Atri, Stefania
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551789/ https://www.ncbi.nlm.nih.gov/pubmed/23259744 http://dx.doi.org/10.1186/1479-5876-10-252

Ejemplares similares

Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1
por: Ruffini, Federica, et al.
Publicado: (2017)

Melanoma cells with acquired resistance to dabrafenib display changes in miRNA expression pattern and respond to this drug with an increase of invasiveness, which is abrogated by inhibition of NF-κB or the PI3K/mTOR signalling pathway
por: Caporali, Simona, et al.
Publicado: (2015)

Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma
por: Ruffini, Federica, et al.
Publicado: (2015)

Exogenous Control of the Expression of Group I CD1 Molecules Competent for Presentation of Microbial Nonpeptide Antigens to Human T Lymphocytes
por: Aquino, Angelo, et al.
Publicado: (2011)

Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib
por: Caporali, Simona, et al.
Publicado: (2017)

Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy
por: Levati, Lauretta, et al.
Publicado: (2022)

miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A
por: Caporali, Simona, et al.
Publicado: (2019)

Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients
por: Carbone, Maria Luigia, et al.
Publicado: (2022)

A novel and atypical NF-KB pro-inflammatory program regulated by a CamKII-proteasome axis is involved in the early activation of Muller glia by high glucose
por: Sbardella, Diego, et al.
Publicado: (2022)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding
por: Graziani, Grazia, et al.
Publicado: (2016)

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
por: Franzese, Ornella, et al.
Publicado: (2017)

CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma
por: Voce, David J., et al.
Publicado: (2021)

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide
por: Tentori, Lucio, et al.
Publicado: (2014)

Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals
por: Tabolacci, Claudio, et al.
Publicado: (2021)

hTERT Transduction Extends the Lifespan of Primary Pediatric Low-Grade Glioma Cells While Preserving the Biological Response to NGF
por: Franzese, Ornella, et al.
Publicado: (2021)

The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells
por: Atzori, Maria Grazia, et al.
Publicado: (2017)

Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma
por: Ceci, Claudia, et al.
Publicado: (2020)

Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models
por: Ceci, Claudia, et al.
Publicado: (2020)

NF-κB as potential target in the treatment of melanoma
por: Madonna, Gabriele, et al.
Publicado: (2012)

Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab
por: Narducci, Maria Grazia, et al.
Publicado: (2020)

Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-κB signaling pathway
por: Zhang, Peng, et al.
Publicado: (2018)

Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance
por: Cristofoletti, Cristina, et al.
Publicado: (2018)

YTHDF2 promotes temozolomide resistance in glioblastoma by activation of the Akt and NF‐κB signalling pathways via inhibiting EPHB3 and TNFAIP3
por: Chen, Yu, et al.
Publicado: (2022)

BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway
por: Li, Mao, et al.
Publicado: (2017)

Naturally reductive metrics and Einstein metrics on compact Lie groups
por: D'Atri, JE, et al.
Publicado: (1979)

XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
por: Hatch, Stephanie B, et al.
Publicado: (2014)

TRAF3 Is Required for NF-κB Pathway Activation Mediated by HTLV Tax Proteins
por: Fochi, Stefania, et al.
Publicado: (2019)

Temozolomide in Combination With NF-κB Inhibitor Significantly Disrupts the Glioblastoma Multiforme Spheroid Formation
Publicado: (2020)

ADAR3 activates NF-κB signaling and promotes glioblastoma cell resistance to temozolomide
por: Raghava Kurup, Reshma, et al.
Publicado: (2022)

The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor
por: Atzori, Maria Grazia, et al.
Publicado: (2022)

NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways
por: Avci, Naze G., et al.
Publicado: (2020)

Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide
por: Wang, Yan, et al.
Publicado: (2021)

Regulation of temozolomide resistance in glioma cells via the RIP2/NF‐κB/MGMT pathway
por: Hu, Yu‐Hua, et al.
Publicado: (2021)

Learning Ceph: a unified, scalable, and reliable open source storage solution
por: D'Atri, Anthony, et al.
Publicado: (2017)

Novel insights into the role of eye movements during REM sleep in memory consolidation
por: Ferrara, Michele, et al.
Publicado: (2023)

Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant
por: Fiorani, Paola, et al.
Publicado: (2009)

Melanoma and Vitiligo: In Good Company
por: Failla, Cristina Maria, et al.
Publicado: (2019)

NF-κB and MicroRNA Deregulation Mediated by HTLV-1 Tax and HBZ
por: Fochi, Stefania, et al.
Publicado: (2019)

Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis
por: Sehm, Tina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s0ai3ipooisn5qfiihgrls0m4v